In plain English
Johnson & Johnson makes pharmaceuticals, medical devices, and consumer health products for patients and consumers worldwide. The company…
Equity · NYSE · USD
JNJ
Johnson & Johnson
$269.98
Today
+$0.79+0.29%
vs previous close
Quote
- Open
- $269.65
- High
- $272.14
- Low
- $269.42
- Prev close
- $269.19
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Size
- Large-cap
- Market cap
- $649.4B
- Shares out
- 2.41B
- Country
- US
- IPO
- Sep 25, 1944
- Exchange
- NYSE
- Website
- jnj.com
- Next earnings
- 2026-10-13 · EPS est. 2.59
Themes
Price chart Pro
Loading chart…
Loading chart…
Company briefing
What JNJ is
Plain English context — why the name shows up in the news, and what to watch next. Not a tip.
Latest on this name
Insights & deeper context
19 recent cards — open any for the full deeper dive.
Johnson & Johnson Drug Shows Improved Mania Symptoms in Bipolar Patients
In brief
Caplyta’s Phase 3 success signals a promising new treatment for acute bipolar mania, potentially boosting JNJ’s earnings and market position in psychopharmacology.
Johnson & Johnson Announces CAPLYTA Demonstrates Reduction In Signs, Symptoms Of Acute Manic Episodes Associated With Bipolar I Disorder In Phase 3 Trial
In brief
CAPLYTA’s Phase 3 success could pave the way for the first approved drug for acute manic episodes, enhancing JNJ’s neuropsychiatry pipeline.
Senator Bets on Small Cap Stocks Ahead of Likely Rate Hike: Why That Could be Risky
In brief
Boozman’s small‑cap tilt before a Fed hike could backfire if borrowing costs spike, weighing on growth‑heavy stocks.
Johnson & Johnson Says Lung Cancer Drug Shows Reduced Side Effects and Longer Patient Survival
In brief
JNJ’s new data show RYBREVANT is safer when given subcutaneously and more effective in a tough NSCLC subgroup, but the market remains wary.
Johnson & Johnson Partner Contineum Slides as Depression Drug Fails
In brief
CTNM shares slid sharply after its Phase 2 depression trial failed to meet the primary endpoint, casting doubt on the drug’s future and impacting both companies’ outlooks.
Contineum’s Phase 2 MOONLIGHT-1 Trial Of JNJ-5120/PIPE-307 Did Not Meet Its Primary Efficacy Endpoint; Analyses Of The Data, Including Prespecified Exploratory Endpoints, Are Ongoing
In brief
The MOONLIGHT‑1 trial did not meet its main goal, raising questions about JNJ‑5120/PIPE‑307’s clinical promise.
Johnson & Johnson Receives CE Marking For ACUVUE OASYS MAX 2-Week, New Reusable Contact Lens Featuring Proprietary MAX Technologies To Deliver Lasting Comfort And Clear Vision, Even At Day 14
In brief
JNJ’s new 2‑week reusable lens clears European regulators, positioning it to capture a larger share of the growing reusable‑lens market.
Timothy Schmid Exercises Options, Realizes $4.39M
In brief
Schmid’s $4.39 million option exercise adds fresh supply to JNJ shares and may dampen short‑term price momentum.
Johnson & Johnson Secures FDA Approval For First Rare Anemia Treatment
In brief
FDA clears JNJ’s first targeted therapy for a rare anemia, opening a new revenue stream and improving treatment options.
Johnson & Johnson Expands Robotic Bronchoscopy Push With AI, 3D Navigation Upgrade
In brief
JNJ’s MONARCH QUEST 3 upgrade, cleared today, adds AI and broader imaging support, positioning the company for stronger growth in robotic bronchoscopy.
EVP At Johnson & Johnson Exercises Options Worth $2.38M
In brief
JNJ insider Taubert exercised $2.38 million worth of options, underscoring management confidence in the stock.
Cullinan Therapeutics Zipalertinib Combo Clears Key Phase 3 Hurdle As First-Line Lung Cancer Treatment Option Takes Shape
In brief
Cullinan Therapeutics' zipalertinib combo cleared a key Phase 3 hurdle, showing strong efficacy and tolerability in a first-line lung cancer treatment option.
Jim Cramer Calls This Industrial Stock ‘Sensational’ And Ameriprise Financial ‘Fantastic’
In brief
Cramer recommends buying Lockheed Martin and Ameriprise Financial shares.
Kathy Hochul Slams Trump Over Medicare Cut, Says 1.3 Million New Yorkers Will Pay More for Prescriptions: 'A New Assault on Seniors...'
In brief
President Trump's decision to end Medicare subsidies will raise prescription drug costs for 1.3 million New Yorkers.
Johnson & Johnson Shares Edge Higher as $3.5B Biotech Moves Expand Oncology Pipeline
In brief
Johnson & Johnson's biotech pipeline expansion could boost the company's oncology business, but investors should consider the potential impact on earnings.
Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation
In brief
JNJ's acquisition of Firefly Bio advances its oncology innovation, but comes with a short-term earnings dilution.
Johnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in vivo CAR-T Programs and Transform Autoimmune Disease Through Immune Reset
In brief
JNJ's collaboration with Sail Biomedicines could lead to significant advancements in autoimmune disease treatment and potentially impact the company's earnings in 2026 and 2027.
Stock Market Today: Dow Jones Futures Gain as Coca-Cola Jumps After Q2 Beat, S&P 500, Nasdaq 100 Decline—Boeing, Johnson & Johnson in Focus (UPDATED)
In brief
The Dow Jones futures gained 0.51%, while Coca-Cola and Boeing reported positive Q2 earnings and revenue beats.
Johnson & Johnson Announces a Proposed Resolution of Ovarian Talc Litigation
In brief
JNJ proposes a comprehensive resolution of ovarian talc litigation, conditioned on 95% claim participation.
Filings & reports
SEC and filing-linked cards
No filings tagged yet
Filing-linked cards for JNJ will show up here when available.
Indexes like the S&P 500 are shown via liquid ETFs (e.g. SPY). Company profile and quotes use live market data when available.